Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Avacta Share Price: Complete Guide to AVCT Stock
Introduction
If you have been searching for Avacta share price information, you are likely tracking Avacta Group plc, a clinical-stage biopharmaceutical company developing innovative cancer treatments. The AVCT ticker has attracted significant attention from investors interested in the biotechnology sector, particularly those following companies with promising oncology platforms.
This guide provides a comprehensive overview of Avacta shares. We will cover what the company does, its current share price, historical performance, financial position, key catalysts, and the factors that influence the stock. Whether you are a beginner investor or an experienced trader, this article will help you make more informed decisions about AVCT.
What Is Avacta Group?
Avacta Group plc is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies. The company is listed on the London Stock Exchange’s AIM market under the ticker symbol AVCT (ISIN: GB00BYYW9G87).
Company Overview
| Attribute | Details |
|---|---|
| Company Name | Avacta Group plc |
| Ticker Symbol | AVCT |
| Exchange | London Stock Exchange AIM |
| Founded | 29 April 2003 |
| Headquarters | London, United Kingdom |
| Sector | Pharmaceuticals & Biotechnology |
| Market Cap | £332.57 million to £344.07 million |
| Shares Outstanding | 471.33 million |
| Fiscal Year End | 31 December |
| CEO | Christina Coughlin |
| ISIN | GB00BYYW9G87 |
The company was founded by Alastair MacLaughlin Smith, Simon Webster, and Kurt Justin Baldwin. It is headquartered at Scale Space, White City, Imperial College Campus, in London.
Proprietary Technology Platforms
Avacta operates through two main proprietary technology platforms:
pre|CISION Platform
This is Avacta’s flagship technology. The pre|CISION platform is a tumor-activated oncology delivery system that uses a highly specific substrate for fibroblast activation protein (FAP). FAP is upregulated in most solid tumors compared with healthy tissues.
The platform works by linking a peptide to an existing cancer drug to inactivate it. The peptide can only be removed by an enzyme found in the tumor (FAP), which means the active drug is released only at the tumor site.
This approach has several advantages:
- The drug remains inactive in the bloodstream, reducing systemic toxicity
- The active drug is concentrated precisely in the tumour
- Side effects are significantly reduced compared to traditional chemotherapy
The company believes this platform has the potential to treat up to 90% of solid tumours by repurposing a range of effective oncology drugs.
Affimer Platform
Avacta also develops powerful diagnostics based on its proprietary Affimer technology. Affimers are small protein-based binding molecules that can be used for diagnostic and therapeutic applications.
Lead Drug Candidates
AVA6000 (faridoxorubicin)
AVA6000 is Avacta’s lead program and a pre|CISION-enabled form of the chemotherapy drug doxorubicin. It is currently in Phase 1 clinical trials. The drug is being studied in several cancer types, including salivary gland cancer, triple negative breast cancer, pancreatic cancer, gastric cancer, small cell lung cancer, and cervical cancer.
Positive health authority interactions have resulted in an increased lifetime maximum dose and an agreement on dose selection for subsequent trials.
AVA6103
AVA6103 is Avacta’s second-generation product. The first patient was treated in the Focus-01 Phase 1 clinical trial on 31 March 2026. Initial clinical data from this program is expected late in the second half of 2026.
AVA6207
AVA6207 is a dual payload program. Updated preclinical data was presented on 21 April 2026, followed by payload selection and clinical candidate selection in the second half of 2026.
Avacta Share Price Overview
Current Trading Information
Avacta shares are traded on the AIM market under the symbol AVCT, with prices quoted in GBX (pence).
Key trading data (as of June 2026):
| Metric | Value |
|---|---|
| Latest price | Approximately 71.00p – 75.00p |
| Day range | 70.00p – 72.00p |
| 52-week range | 28.00p – 92.00p |
| Market capitalisation | £332.57 million – £344.07 million |
| Shares outstanding | 471.33 million |
| Average volume | 2.25 million |
| Beta | 0.56 |
The share price has seen significant movement over the past year. According to MarketWatch data, the 52-week range is 28.00p to 92.00p. The stock has exhibited substantial volatility, with a 1-year change of approximately 136.67%.
Recent Performance
Recent trading data shows the following price action:
| Date | Close (p) | Change | Volume |
|---|---|---|---|
| 15 Jun 2026 | 71.00 | 0.00% | 761,071 |
| 12 Jun 2026 | 71.00 | +3.65% | 1,448,618 |
| 11 Jun 2026 | 68.50 | – | 1,344,747 |
| 10 Jun 2026 | 68.50 | -2.84% | 2,673,151 |
Recent Share Price Catalysts
22 June 2026: Avacta shares rose 2.7% to 75.00 pence following the company’s annual general meeting, where CEO Christina Coughlin highlighted “strong progress” in the first half of 2026.
19 June 2026: Shares were trading at approximately 72.00p – 74.00p.
5 June 2026: The company announced an oversubscribed strategic equity fundraise of £9 million at 70 pence per share.
Factors Affecting Avacta Share Price
Clinical Trial Results
As a clinical-stage biopharmaceutical company, Avacta’s share price is heavily influenced by clinical trial data. Positive results from the AVA6000 and AVA6103 programs can lead to significant share price increases, while disappointing results can cause sharp declines.
The company expects several key data readouts:
- AVA6000: Further Phase 1 data expected in late 2026
- AVA6103: Initial clinical data expected in late H2 2026
- AVA6207: Payload selection and clinical candidate selection in H2 2026
Partnering and Commercial Discussions
Avacta is in constructive partnering discussions with multiple parties on assets across its pipeline. These discussions involve first-, second-, and third-generation assets. Any announcement of a partnership or licensing deal could be a major catalyst for the share price.
Financing and Cash Position
Avacta has raised significant capital in recent years. The company has raised £41.5 million in the last 18 months. Recent financings include:
- March 2026: £10 million oversubscribed placing and subscription
- June 2026: £9 million oversubscribed strategic equity fundraise at 70p per share
The company’s cash runway now extends into early Q1 2027.
Market Sentiment and Biotechnology Sector
Avacta operates in the biotechnology sector, which is known for its volatility. The sector is often driven by market sentiment, risk appetite, and broader economic conditions. Factors such as interest rates, inflation, and overall market conditions can affect investor appetite for high-risk, high-reward biotech stocks.
Financial Performance
Full Year 2024 Results
Avacta reported its preliminary results for the year ended 31 December 2024:
- Revenue: £24.42 million (up from the prior year)
- Therapeutics revenue: £0.11 million (down from £2.85 million, reflecting the absence of milestones from AffyXell)
- Research and development costs: £18.8 million
- Pre-tax loss from continuing operations: £28.98 million (narrower than £31.13 million in 2023)
- Total loss for the year: £52.84 million (including impairments of £22.41 million on assets held for sale)
- Cash at year end: £12.9 million
- Cash after divestment (April): £17.3 million
Financial Position
The company’s financial position has been strengthened by recent equity raises and the divestment of its diagnostics division, Launch Diagnostics. The divestment has significantly reduced liabilities and non-core assets, allowing Avacta to focus entirely on its therapeutics business.
Key Financial Metrics
| Metric | Value |
|---|---|
| EPS | -£0.10 |
| P/E Ratio | N/A (company not profitable) |
| Dividend Yield | 0% |
| Return on Equity | Negative |
Analyst Ratings and Price Targets
According to StockAnalysis.com, the consensus rating for Avacta Group is “Buy” with an average price target of 82.33p, which represents an 8.33% upside from the current price.
Other price targets include 86.50p (+15.33% upside).
However, it is important to note that analyst ratings are opinions and not guarantees of future performance. Investors should conduct their own research.
Recent News and Developments
June 2026: Strong Progress in First Half
At the company’s annual general meeting on 22 June 2026, CEO Christina Coughlin reported that Avacta had “continued its strong progress” in the first half of the year.
Key highlights included:
- Initiation of the clinical programme with AVA6103
- Updated data on AVA6000 further validating the pre|CISION technology
- Strengthened leadership team with Richard Hughes as non-executive chairman
- Extended cash runway into early Q1 2027
June 2026: £9 Million Strategic Equity Fundraise
Avacta raised approximately £9 million from institutional investors and existing shareholders at an issue price of 70 pence per share. The funds are being used for convertible bond repayments.
CEO Christina Coughlin commented: “This Placing enables Avacta to retain the value of our equity while further reinforcing our financial position by reducing the outstanding debt in the Convertible Bond.”
May 2026: Board Director Changes
Shaun Chilton, who was appointed to the Board in 2022 and served as non-executive Chairman since 2024, decided not to seek re-election at the AGM. The company is conducting a recruitment process for a nonexecutive deputy chairman.
April 2026: Q1 Business Update
Avacta completed a successful financing with an oversubscribed placing and subscription raising £10 million, extending the cash runway into early Q1 2027 and allowing the company to retain 100% ownership of all assets in the pipeline.
February 2026: Appointment of Chief Scientific Officer
Avacta appointed Francis Wilson as its chief scientific officer. Wilson brings expertise in chemistry, particularly in the development of innovative therapeutic approaches.
How to Buy Avacta Shares
Trading Platforms
Avacta shares can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSE). The shares are traded in pence (GBX).
Key Trading Information
- Exchange: London Stock Exchange AIM
- Symbol: AVCT
- Currency: GBX (pence)
- Trading hours: Generally 8:00 AM to 4:30 PM GMT
- ISIN: GB00BYYW9G87
Investment Considerations
Investments on the AIM market can be higher risk and have lower liquidity, meaning they can be harder to buy or sell, and their prices may be more volatile. Before investing, make sure you understand the risks.
Risks and Considerations
Clinical Trial Risk
As a clinical-stage biopharmaceutical company, Avacta faces the risk that its drug candidates may not demonstrate safety and efficacy in clinical trials. There is no guarantee that AVA6000, AVA6103, or any other product will receive regulatory approval.
Funding Risk
While Avacta has extended its cash runway into early Q1 2027, the company may require additional financing in the future to fund its clinical programs. Any future fundraises could dilute existing shareholders.
Regulatory Risk
The company’s products are subject to regulation by health authorities in multiple jurisdictions. Changes in regulatory requirements or delays in approvals could affect the company’s timeline and share price.
Competition
Avacta operates in a competitive field with many other companies developing cancer therapies. The company’s success depends on its ability to differentiate its products and demonstrate superior efficacy or safety.
AIM Listing
As an AIM-listed company, Avacta is subject to different regulatory requirements than companies on the main market of the London Stock Exchange. AIM companies can be more volatile and have lower liquidity.
Common Mistakes Investors Make
Focusing Only on the Share Price
Many investors look only at the share price without understanding the company’s fundamentals, pipeline, and financial position. A low share price does not necessarily mean a stock is undervalued.
Overlooking Clinical Trial Risks
Biotech investing is inherently risky. Investors should not assume that clinical trial success is guaranteed or that positive early-stage results will necessarily lead to regulatory approval.
Chasing Momentum
Avacta has experienced significant price swings. Investors who buy after a sharp rise may find themselves exposed to a subsequent decline.
Ignoring Dilution Risk
As a clinical-stage company, Avacta may need to raise additional capital through share placings, which can dilute existing shareholders.
Not Understanding the Technology
The pre|cision platform is complex. Investors should take time to understand how the technology works and its potential advantages and limitations.
Expert Insights
Avacta represents a classic clinical-stage biotech investment. The company’s pre|CISION platform has the potential to address a significant unmet need in oncology by reducing the toxicity of existing cancer drugs. The platform’s ability to target FAP, which is upregulated in up to 90% of solid tumors, provides a broad addressable market.
The company’s transformation from a diagnostics-focused business to a pure-play oncology therapeutics company is notable. The divestment of Launch Diagnostics has allowed Avacta to focus entirely on its core pipeline.
The recent fundraises at 70 pence per share provide a reference point for the company’s valuation. The fact that the June 2026 fundraise was oversubscribed suggests institutional confidence in the company’s prospects.
Key catalysts to watch include:
- Initial clinical data from AVA6103 in late H2 2026
- Further Phase 1 data on AVA6000
- Any partnering announcements
- Progress on the AVA6207 dual payload programme
The company’s cash runway into early Q1 2027 provides funding beyond multiple value-inflection points, including initial clinical data on AVA6103.
Actionable Recommendations
For Beginners
- Do your own research. Do not rely solely on share price movements or tips from online forums. Read the company’s announcements, annual reports, and clinical trial updates.
- Understand the risks. Biotech investing is high-risk, high-reward. Only invest money you can afford to lose.
- Start small. If you decide to invest, consider starting with a small position while you learn more about the company and the sector.
- Use a reputable broker. Ensure your brokerage platform supports trading on the London Stock Exchange AIM market.
For Experienced Investors
- Monitor clinical trial data. Pay close attention to data readouts from AVA6000 and AVA6103. These announcements are the primary catalysts for the share price.
- Track financing activities. Monitor announcements regarding fundraises, which can dilute existing shareholders but also provide the capital needed for clinical development.
- Watch for partnering news. Any announcement of a partnership or licensing deal could be a major positive catalyst.
- Review the company’s cash position. Understanding how much cash the company has and its burn rate will help you assess how long it can fund operations without additional financing.
Frequently Asked Questions
What is the Avacta share price?
As of June 2026, Avacta shares were trading at approximately 71.00p to 75.00p. However, share prices change constantly. For the most current price, check a financial data provider or your brokerage platform.
What does AVCT stand for?
AVCT is the ticker symbol for Avacta Group plc on the London Stock Exchange AIM market.
What is Avacta’s pre|CISION technology?
Pre|cision is Avacta’s proprietary tumor-activated oncology delivery platform. It uses a peptide to inactivate a cancer drug in the bloodstream, with the drug only being released at the tumour site by an enzyme called FAP. This reduces systemic toxicity and concentrates the drug where it is needed.
Is Avacta a good investment?
Whether AVCT is a good investment depends on your individual financial situation, risk tolerance, and investment goals. Avacta is a high-risk clinical-stage biotech company with significant volatility. It is not suitable for all investors. Always conduct your own research or consult a financial advisor.
Does Avacta pay a dividend?
No. Avacta does not pay a dividend. The company is focused on clinical development and is not profitable.
What is the market capitalization of Avacta?
The market capitalization is approximately £332.57 million to £344.07 million.
Who is the CEO of Avacta?
The CEO of Avacta is Christina Coughlin.
What are Avacta’s lead drug candidates?
Avacta’s lead programs are AVA6000 (faridoxorubicin), a pre|CISION-enabled form of doxorubicin in Phase 1 trials, and AVA6103, a second-generation product that entered Phase 1 trials in March 2026.
How can I buy Avacta shares?
Avacta shares can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSE).
What is the analyst rating for Avacta?
The consensus rating for Avacta is “Buy” with an average price target of approximately 82.33p.
Conclusion
Avacta Group plc (AVCT) is a clinical-stage biopharmaceutical company developing innovative cancer treatments through its proprietary pre|CISION platform. The share price has experienced significant volatility, with a 52-week range of 28.00p to 92.00p, reflecting both the potential of the company’s technology and the inherent risks of clinical-stage biotech investing.
The company has made substantial progress in 2026, initiating the clinical programme for AVA6103, presenting updated data on AVA6000, and raising significant capital to extend its cash runway into early Q1 2027. The company is actively pursuing partnering discussions for its pipeline assets.
Key catalysts to watch include initial clinical data from AVA6103 in late H2 2026, further data from AVA6000, and any partnering announcements. With a strengthened balance sheet and a pipeline of promising drug candidates, Avacta is positioned for what the company describes as a “potentially transformative period.”
As with any investment, thorough research and careful consideration of your financial situation and risk tolerance are essential. Always consult with a qualified financial advisor before making investment decisions.
[…] Read More: Avacta Share Price: AVCT Stock Guide 2026 […]